全球抗菌药物消耗:世界卫生组织抗微生物药物耐药性全球行动计划与2019冠状病毒病(COVID-19)大流行的影响
该研究采用2014年8月至2020年8月全球月度抗菌药物(抗生素、抗病毒药和抗真菌药)采购数据的横断面时间序列分析,评估WHO抗微生物药物耐药性全球行动计划(GAP-AMR)在大流行前的效果及COVID-19大流行对全球抗菌药物消耗的影响。大流行前全球抗菌药物消耗下降,发达国家降幅大于发展中国家(-8.4%,P=0.020 vs -1.2%,P=0.660);2020年3月较2019年上升11.2%(P<0.001);2020年4月至8月全球较上年下降18.7%(P<0.001)。
要点
- 大流行前全球抗菌药物消耗下降,发达国家降幅大于发展中国家(-8.4%,P=0.020 vs -1.2%,P=0.660)。
- 2020年3月抗菌药物消耗较2019年上升11.2%(P<0.001),抗病毒药增幅最大。
- 2020年4月至8月全球抗菌药物消耗较上年下降18.7%(P<0.001)。
核心结论
- 大流行前全球抗菌药物消耗的下降提示WHO GAP-AMR产生了积极影响。
- 大流行期间抗菌药物消耗先升后降;作者认为AMR计划应明确措施,确保在COVID-19等卫生危机期间充分落实AMR行动。
研究设计与样本
- 横断面时间序列分析,数据集为2014年8月至2020年8月抗菌药物(抗生素、抗病毒药和抗真菌药)的月度采购数据。
- 以大流行前每1000人群抗菌药物消耗量按经济发展状况用线性回归模型评估;用干预性自回归积分滑动平均(ARIMA)模型检验大流行宣布(2020年3月)及2020年4月至8月第一阶段全球和按国家发展状况的显著变化。
主要发现
- 大流行前抗菌药物消耗全球下降,发达国家降幅大于发展中国家(-8.4%,P=0.020 vs -1.2%,P=0.660)。
- 2020年3月抗菌药物消耗较2019年上升11.2%(P<0.001)。
- 2020年3月抗病毒药增幅最大,发达国家为48.2%(P<0.001),发展中国家为110.0%(P<0.001);其次为抗生素,发达国家为6.9%(P<0.001),发展中国家为5.9%(P=0.003)。
- 2020年4月至8月全球抗菌药物消耗较上年下降18.7%(P<0.001)。
- 2020年4月至8月抗生素消耗在发达国家下降28.0%(P<0.001),在发展中国家下降16.8%(P<0.001)。
关键数值与推荐
- 原文未报告指南或共识推荐条款。
临床怎么用
- 原文结论建议AMR计划应明确措施,确保在COVID-19等卫生危机期间充分落实AMR行动。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the effect of the COVID-19 pandemic on antimicrobial consumption worldwide. OBJECTIVES: To describe the impact of the WHO Global Action Plan on Antimicrobial Resistance (GAP-AMR) on antimicrobial consumption pre-pandemic and to evaluate the impact of the COVID-19 pandemic on antimicrobial consumption worldwide. METHODS: A cross-sectional time-series analysis using a dataset of monthly purchases of antimicrobials (antibiotics, antivirals and antifungals) from August 2014 to August 2020. Antimicrobial consumption per 1000 population was assessed pre-pandemic by economic development status using linear regression models. Interventional autoregressive integrated moving average (ARIMA) models tested for significant changes with pandemic declaration (March 2020) and during its first stage from April to August 2020, worldwide and by country development status. RESULTS: Prior to the pandemic, antimicrobial consumption decreased worldwide, with a greater apparent decrease in developed versus developing countries (-8.4%, P = 0.020 versus -1.2%, P = 0.660). Relative to 2019, antimicrobial consumption increased by 11.2%, P < 0.001 in March 2020. The greatest increase was for antivirals in both developed and developing countries (48.2%, P < 0.001; 110.0%, P < 0.001) followed by antibiotics (6.9%, P < 0.001; 5.9%, P = 0.003). From April to August 2020, antimicrobial consumption decreased worldwide by 18.7% (P < 0.001) compared with the previous year. Specifically, antibiotic consumption significantly decreased in both developed and developing countries (-28.0%, P < 0.001; -16.8%, P < 0.001). CONCLUSIONS: The global decrease in antimicrobial consumption pre-pandemic suggests a positive impact of the WHO GAP-AMR. During the pandemic, an initial increase in antimicrobial consumption was followed by a decrease worldwide. AMR plans should specify measures to ensure full implementation of AMR efforts during health crises such as the COVID-19 pandemic.
引用
- Khouja T, Mitsantisuk K, Tadrous M, et al. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19). J Antimicrob Chemother. 2022. PMID: 35178565. doi:10.1093/jac/dkac028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。